Backus William A. 4

4 · BALCHEM CORP · Filed Aug 1, 2024

Form 4

Period: 2024-07-30

VP & Chief Accounting Officer

Transactions

Exercise/Conversion
Stock Options (right to buy)
2024-07-30−3,900→ 0 total
Exercise: $84.09Exp: 2029-02-13→ Common Stock (3,900 underlying)
Sale
Common Stock
2024-07-30$180.47/sh−330$59,554→ 4,988 total
Exercise/Conversion
Common Stock
2024-07-30$84.09/sh+3,900$327,951→ 8,888 total
Sale
Common Stock
2024-07-30$179.25/sh−3,570$639,912→ 5,318 total
Sale
Common Stock
2024-07-30$177.10/sh−904$160,094→ 132 total(indirect: By 401(k))

Footnotes (6)

[F1]Exercise of fully vested non-qualified stock options.
[F2]This transaction was executed in multiple sales ranging from $179.0200 to $179.9700 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or any security holder of the issuer full information regarding the number of shares and prices at which the transactions were affected regarding this footnote.
[F3]This transaction was executed in multiple sales ranging from $180.3050 to $180.5900 per share, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or any security holder of the issuer full information regarding the number of shares and prices at which the transactions were affected regarding this footnote.
[F4]Intra-plan transfer from the Balchem Common Stock Fund to another fund within the Balchem Corporation 401(k) plan.
[F5]Reflects shares previously acquired under the Balchem Corporation 401(k) plan.
[F6]Stock options that vested 20% on February 13, 2020, 40% on February 13, 2021, and 40% on February 13, 2022, and are exercisable.

Documents

1 file